Author:
Ngemu Erastus K,Khayeka-Wandabwa Christopher,Kweka Eliningaya J,Choge Joseph K,Anino Edward,Oyoo-Okoth Elijah
Abstract
Abstract
Background
Ensuring that no baby is born with HIV is an essential step towards achieving an AIDS-free generation. To achieve this, strategies that decouple links between childbirth and HIV transmission are necessary. Traditional forms of prevention of mother-to-child transmission of HIV (PMTCT), has been recommended. Recognizing the importance and challenges of combination of methods to achieve rapid PMTCT, the World Health Organization (WHO) recommended option B Highly Active Antiretroviral Therapy (HAART) for all HIV-positive pregnant women. This study aimed to evaluate the effectiveness of the HAART in PMTCT. A cohort of HIV-infected pregnant women in Kenya were obtained from the DREAM Center, Nairobi. The study participants underwent adherence counselling and Option B of HAART [Nevirapine(NVP) + Lamivudine + Zidovudine] at the fourth week of gestation followed by an intravenous NVP administration intrapartum and postpartum NVP syrup to the respective infants for six weeks. Absolute pre-HAART and post-HAART CD4 counts and viral loads counts were determined. Comparison of the CD4 counts and viral loads before and after administration of HAART were done using Wilcoxon’s Matched Pairs Signed-Ranks Test.
Findings
The mean absolute CD4 cell counts in mothers after administration of HAART was significantly higher (Z = 15.664, p < 0.001) than before the administration of HAART). Also the viral load of the mothers significantly (Z = 11.324, p < 0.001) reduced following HAART treatment. Following the HAART administration in mothers, up to 90% of children were confirmed to be HIV negative.
Conclusion
Administration of HAART to mothers and children demonstrated an effective mechanism of PMTCT. However, other aspects of HAART such as adherence, costs, mothers behaviour during HAART, and the child feeding programme during the therapy should further be evaluated and ascertained how they can affect the overall efficacy of option B HAART in PMTCT.
Publisher
Springer Science and Business Media LLC
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference39 articles.
1. Bositis CM, Gashongore I, Patel DM: Updates to the World Health Organization’s recommendations for the use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. Med J Zambia. 2010, 37: 111-117.
2. NASCOP: Guidelines for prevention of mother to child transmission (PMTCT) of HIV/AIDS in Kenya fourth edition. 2012, Kenya: Ministry of Health, Available at http://nascop.or.ke/library/pmtct/Guidelines%20for%20PMTCT%20of%20HIVAIDS%20in%20Kenya-1.pdf
3. UNAIDS: UNAIDS Report on the global AIDS epidemic. 2012, Geneva: WHO
4. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA: Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS. 2008, 22: 973-981. 10.1097/QAD.0b013e3282f9b67a.
5. Cooper E, Charurat M, Mofenson L, et al: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. Acquir Immune Defic Syndr. 2002, 29: 484-494. 10.1097/00126334-200204150-00009.
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献